SAN DIEGO, Aug. 23, 2018 /PRNewswire/ -- Evofem
Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a
clinical-stage biopharmaceutical company committed to developing
and commercializing innovative products to address unmet needs in
women's sexual and reproductive health, announced today that the
Company will present at the 20th Annual Rodman & Renshaw Global
Investment Conference, sponsored by H.C. Wainwright & Co., LLC,
as follows:
Date:
|
Thursday, September
6, 2018
|
Time:
|
11:40 a.m.
EDT
|
Location:
|
Fontainebleau Foyer
(2nd floor), St. Regis New York Hotel, New York City
|
Webcast
(live and archive):
|
www.evofem.com in the "Investors" section under
"Events and Presentations."
|
Evofem's management team will also be available for one-on-one
meetings with investors during the conference. Institutional
investors who would like to attend the presentation or schedule a
one-on-one meeting with the Company may register for the conference
at http://www.rodmanevents.com.
Evofem's lead product candidate, Amphora® (L-lactic acid,
citric acid, and potassium bitartrate) vaginal gel, is being
studied as a non-hormonal, on-demand vaginal contraceptive and for
the prevention of certain sexually transmitted infections.
The Company expects to report top-line data by year-end 2018
from its confirmatory Phase 3 clinical trial of Amphora for
contraception. Assuming positive results, Evofem expects to
re-submit the Amphora New Drug Application (NDA) in the first half
of 2019 which, if approved by the FDA, would position the Company
to commercialize Amphora as the first and only hormone-free,
on-demand contraceptive drug in early 2020.
A Phase 2b clinical trial of
Amphora for the prevention of urogenital acquisition
of Chlamydia trachomatis (primary endpoint)
and Neisseria gonorrhea in women is also
underway.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is a clinical-stage biopharmaceutical company
committed to developing and commercializing innovative products to
address unmet needs in women's sexual and reproductive health.
Evofem is leveraging its proprietary Multi-purpose Prevention
Technology vaginal gel to develop product candidates for multiple
indications, including contraception, the prevention of urogenital
transmission of chlamydia and gonorrhea in women, and recurrent
bacterial vaginosis. For more information regarding Evofem, please
visit www.evofem.com.
Forward-Looking Statements
Statements in this press
release about Evofem's future expectations, plans and prospects, as
well as any other statements regarding matters that are not
historical facts, may constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. These statements are often characterized by terminology such
as "believes," "hopes," "may," "anticipates," "should," "intends,"
"plans," "will," "expects," "estimates," "projects," "positioned,"
"strategy" and similar expressions and are based on assumptions and
assessments made in light of management's experience and perception
of historical trends, current conditions, expected future
developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties, many of which are
outside of the Company's control. Important factors that could
cause actual results, developments, and business decisions to
differ materially from forward-looking statements are described in
the sections titled "Risk Factors" in the Company's filings with
the Securities and Exchange Commission (SEC), including its
Quarterly Report for the period ended March 31, 2018, as filed
with the SEC on Form 10-Q on May 14, 2018, and include but are
not limited to the following: objectives, plans and strategies as
well as statements, other than historical facts, that address
activities, events or developments that the Company intends,
expects, projects, believes or anticipates will or may occur in the
future; risks and uncertainties associated with market conditions;
statements about the anticipated results of the Phase 3
clinical trial evaluating Amphora as a contraceptive and the
Phase 2b clinical trial of Amphora to prevent urogenital
acquisition of Chlamydia
trachomatis and Neisseria gonorrhea in
women, and any expected completion dates or general timing for
these clinical trials; the Company's reliance on third parties to
conduct its clinical trials, research and development and
manufacturing; the availability of reimbursement from government
authorities and health insurance companies for the Company's
products; the impact of potential product liability lawsuits; the
influence of extensive and costly government regulation; the
volatility of the trading price of the Company's common stock, and
the concentration of power in its stock ownership. Forward-looking
statements in this press release are made as of the date of this
press release, and the Company undertakes no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. These forward-looking statements should
not be relied upon as representing Evofem's views as of any date
subsequent to the date hereof.
Investor Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
O: 858-550-1900 x167
Media Contact
Sophia
Ononye
RXMD
evofem@rxmedyn.com
O: (646) 599-8630
M: (917) 557-1909
View original content with
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-20th-annual-global-investment-conference-on-september-6-2018-300701176.html
SOURCE Evofem Biosciences, Inc.